Advantage Alpha Capital Partners LP Castle Biosciences Inc Transaction History
Advantage Alpha Capital Partners LP
- $419 Million
- Q3 2024
A detailed history of Advantage Alpha Capital Partners LP transactions in Castle Biosciences Inc stock. As of the latest transaction made, Advantage Alpha Capital Partners LP holds 10,940 shares of CSTL stock, worth $303,256. This represents 0.07% of its overall portfolio holdings.
Number of Shares
10,940Holding current value
$303,256% of portfolio
0.07%Shares
1 transactions
Others Institutions Holding CSTL
# of Institutions
201Shares Held
24.5MCall Options Held
303KPut Options Held
30.3K-
Black Rock Inc. New York, NY3.04MShares$84.4 Million0.0% of portfolio
-
Wasatch Advisors Inc Salt Lake City, UT1.83MShares$50.6 Million0.26% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.75MShares$48.5 Million0.0% of portfolio
-
Bellevue Group Ag Kuesnacht, V81.26MShares$35 Million0.61% of portfolio
-
Portolan Capital Management, LLC Boston, MA1.26MShares$34.8 Million2.85% of portfolio
About CASTLE BIOSCIENCES INC
- Ticker CSTL
- Exchange NASDAQ
- Sector Healthcare
- Industry Diagnostics & Research
- Shares Outstandng 26,297,000
- Market Cap $729M
- Description
- Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company als...